These results provide more evidence for EBP50 as a tumor suppressor in breast cancer cell lines, and reveal an attractive mechanism that explains EBP50 tumor suppressor activity in mammary glands by counteracting the EGFR pro-oncogenic pathway. This evidence concerns the gene NHERF1 and neoplasm.